Gossamer Bio is a clinical‑stage biopharma developing seralutinib, an inhaled small‑molecule inhibitor of PDGFRα/β, CSF1R, and c‑KIT, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The drug is delivered via a dry‑powder inhaler to target lung tissue directly, aiming to reduce vascular inflammation, proliferation, and fibrosis while minimizing systemic side effects. Seralutinib is currently in Phase 3 trials following promising Phase 2 results.
Funding
$212M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD) face progressive vascular remodeling, inflammation, and fibrosis that lead to high morbidity, limited treatment options, and poor survival rates. Existing therapies are administered systemically and do not directly target the diseased lung tissue, resulting in suboptimal efficacy and systemic side effects.
Solution
Gossamer Bio is developing seralutinib, an inhaled small‑molecule inhibitor of PDGFRα/β, CSF1R, and c‑KIT, to be delivered via a dry‑powder inhaler directly to the lungs. By concentrating drug exposure at the site of disease, seralutinib aims to reduce pulmonary vascular inflammation, cellular proliferation, and fibrosis, potentially slowing or reversing disease progression. The inhaled route also minimizes systemic exposure, improving safety compared with oral kinase inhibitors. Seralutinib is currently in a Phase 3 PROSERA trial for PAH and a Phase 3 registrational trial for PH‑ILD, building on positive Phase 2 TORREY data that demonstrated improvements in hemodynamics and right‑heart function.
Target Audience
Primary customers are pharmaceutical developers, clinical investigators, and healthcare providers treating patients with rare, progressive pulmonary hypertension conditions (PAH and PH‑ILD).
Features
- Inhaled delivery via a dry‑powder inhaler for targeted lung exposure
- Multi‑kinase inhibition (PDGFRα/β, CSF1R, c‑KIT) addressing key pathways in vascular remodeling
- Small‑molecule formulation enabling oral‑inhalation dosing without complex biologics
- Designed to reduce systemic side effects while maximizing pulmonary efficacy
- Advanced through Phase 3 clinical programs (PROSERA for PAH, global Phase 3 for PH‑ILD)
- Demonstrated hemodynamic and right‑heart functional improvements in Phase 2 TORREY study